A Recombinant Antigen Recognized by Fasciola Hepatica–infected Hosts

Silva, Elisabete; Castro, Albert; Lopes, Antônio Carneiro; Castro-Rodrigues, Artur F.; Dias, César; Conceição, Antónia; Alonso, J.M.; Costa, José Manuel Correia da; Bastos, Maria de Lourdes; Parra, Francisco; Moradas‐Ferreira, Pedro; Silva, Maria João

doi:10.1645/ge-136r

Cited by 22 publications

(22 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…has shown high sensitivity and specificity in the diagnosis of human fascioliasis [23]. Several groups have reported the purification of the immunodominant antigens from the ES products of the liver fluke [24,25]. Of these, only one group described the use of a purified 27 kDa cysteine proteinase from Japanese Fasciola spp.…”

Section: Discussionmentioning

confidence: 99%

Dot-Blot Immunoassay of Fasciola gigantica Infection using 27 kDa and Adult Worm Regurge Antigens in Egyptian Patients

Kamel

Sarhan

2013

Korean J Parasitol

View full text Add to dashboard Cite

The purpose of the present study was to evaluate the potential role of the 27-Kilodalton (KDa) antigen versus Fasciola gigantica adult worm regurge antigens in a DOT-Blot assay and to assess this assay as a practical tool for diagnosis fascioliasis in Egyptian patients. Fasciola gigantica antigen of an approximate molecular mass 27-(KDa) was obtained from adult worms by a simple elution SDS-PAGE. A Dot-Blot was developed comparatively to adult worm regurge antigens for the detection of specific antibodies from patients infected with F. gigantica in Egypt. Control sera were obtained from patients with other parasitic infections and healthy volunteers to assess the test and compare between the antigens. The sensitivity, specificity, positive and negative predictive values of Dot-Blot using the adult worm regurge were 80%, 90%, 94.1%, and 69.2% respectively, while those using 27-KDa were 100% which confirms the diagnostic potential of this antigen. All patients infected with Fasciola were positive, with cross reactivity reported with Schistosoma mansoni serum samples. This 27-KDa Dot-Blot assay showed to be a promising test which can be used for serodiagnosis of fascioliasis in Egyptian patients especially, those presenting with hepatic disease. It is specific, sensitive and easy to perform method for the rapid diagnosis particularly when more complex laboratory tests are unavailable.

show abstract

Section: Discussionmentioning

confidence: 99%

Dot-Blot Immunoassay of Fasciola gigantica Infection using 27 kDa and Adult Worm Regurge Antigens in Egyptian Patients

Kamel

Sarhan

2013

Korean J Parasitol

View full text Add to dashboard Cite

show abstract

“…The Fh8 is a small antigen (8 kDa) excreted-secreted by the parasite F. hepatica in the early stages of infection (Silva et al, 2004). This protein is located on the surface of the parasite, and it was suggested as a useful tool for the diagnosis, vaccine, and drug development against F. hepatica infections (Silva et al, 2004).…”

Section: The Novel Fh8 Fusion System (Hitag®)mentioning

confidence: 99%

Fusion tags for protein solubility, purification and immunogenicity in Escherichia coli: the novel Fh8 system

et al. 2014

View full text Add to dashboard Cite

Proteins are now widely produced in diverse microbial cell factories. The Escherichia coli is still the dominant host for recombinant protein production but, as a bacterial cell, it also has its issues: the aggregation of foreign proteins into insoluble inclusion bodies is perhaps the main limiting factor of the E. coli expression system. Conversely, E. coli benefits of cost, ease of use and scale make it essential to design new approaches directed for improved recombinant protein production in this host cell. With the aid of genetic and protein engineering novel tailored-made strategies can be designed to suit user or process requirements. Gene fusion technology has been widely used for the improvement of soluble protein production and/or purification in E. coli, and for increasing peptide’s immunogenicity as well. New fusion partners are constantly emerging and complementing the traditional solutions, as for instance, the Fh8 fusion tag that has been recently studied and ranked among the best solubility enhancer partners. In this review, we provide an overview of current strategies to improve recombinant protein production in E. coli, including the key factors for successful protein production, highlighting soluble protein production, and a comprehensive summary of the latest available and traditionally used gene fusion technologies. A special emphasis is given to the recently discovered Fh8 fusion system that can be used for soluble protein production, purification, and immunogenicity in E. coli. The number of existing fusion tags will probably increase in the next few years, and efforts should be taken to better understand how fusion tags act in E. coli. This knowledge will undoubtedly drive the development of new tailored-made tools for protein production in this bacterial system.

show abstract

“…Although several recombinant proteins have been widely employed as potential vaccines against F. hepatica (Muro et al, 1997, Kofta et al, 2000, Dalton et al, 2003, , Law et al, 2003,), their usefulness for the diagnosis of fascioliasis have only been evaluated in experimental animals (Cornelissen et al, 2001, Silva et al, 2004, Paz-Silva et al, 2005, Arias et al, 2006). In this publication the recombinant form of a novel member of the F. hepatica saposin-like-2 protein family (FhSAP2) was employed to detect antibodies in the sera of subjects that live in endemic areas and that had been confirmed positive to fascioliasis by the presence of F. hepatica egg in feces.…”

Section: Introductionmentioning

confidence: 99%

Fasciola hepatica saposin-like protein-2–based ELISA for the serodiagnosis of chronic human fascioliasis

Figueroa-Santiago

Delgado

Espino

2011

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

An indirect enzyme-linked immunosorbent assay (ELISA) was developed and evaluated for its diagnostic ability to detect human IgG antibodies against Fasciola hepatica saposin-like protein-2. The assay was compared with an indirect ELISA with excretory-secretory products (FhES) from adult F. hepatica. In an analysis of the sera of 37 patients infected with F. hepatica, 40 patients with other parasitic infections, and 50 healthy controls, the sensitivity of both ELISA assays was 100%. However, the FhSAP2-based ELISA was more specific (95.6%) than the FhES-ELISA (91.9%). These results demonstrated that FhSAP2 can be used in the serodiagnosis of chronic human fascioliasis with additional advantage that is relative cheap and easy to produce. Studies are in progress to evaluate this FhSAP2-ELISA assay in a large-scale prevalence surveys in endemic areas.

show abstract

A Recombinant Antigen Recognized by Fasciola Hepatica–infected Hosts

Cited by 22 publications

References 19 publications

Dot-Blot Immunoassay of Fasciola gigantica Infection using 27 kDa and Adult Worm Regurge Antigens in Egyptian Patients

Dot-Blot Immunoassay of Fasciola gigantica Infection using 27 kDa and Adult Worm Regurge Antigens in Egyptian Patients

Fusion tags for protein solubility, purification and immunogenicity in Escherichia coli: the novel Fh8 system

Fasciola hepatica saposin-like protein-2–based ELISA for the serodiagnosis of chronic human fascioliasis

Contact Info

Product

Resources

About